Will the Inflation Reduction Act Impact Drug Development Decisions?
The short answer is yes. In fact, passage of the Inflation Reduction Act (H.R. 5376)…
CertaraJanuary 27, 2023
How Drug Developers can Navigate the Inflation Reduction Act of 2022
Learn how the IRA will impact how new drugs are marketed and why negotiating pricing…
CertaraJanuary 27, 2023
Exceling at Accelerating in Rare Disease Drug Development
By: Rajesh Krishna, PhD, FAAPS and Steve Sibley According to the National Institutes of Health,…
CertaraJanuary 26, 2023
Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
An novel single dose regimen of tremelimumab combined with durvalumab could be a way to…
CertaraJanuary 26, 2023
Tips & Tricks for Streamlining Non-compartmental Pharmacokinetic Analysis
These Phoenix tips and tricks will help you exclude Lambda Z, name partial areas, and…
CertaraJanuary 20, 2023
D360 as your organization’s extendable and central data engine
D360 is an industry-leading scientific data informatics platform providing a flexible, scalable, and customizable enterprise…
CertaraJanuary 20, 2023
Physiologically-Based Pharmacokinetic Modeling & Simulation to Support Asciminib NDA Submission & Inform Drug Product Label
Physiologically based pharmacokinetic (PBPK) modeling and simulation has become an established approach to assess drug-drug…
CertaraJanuary 13, 2023
Certara Awarded NIH Contract for Toxicology Consulting Support
Certara toxicology experts to support NIH’s BPN and HEAL drug development programs for nervous system…
CertaraJanuary 10, 2023
